Keros Therapeutics 株価情報 (NASDAQ: KROS)

Keros Therapeutics (NASDAQ:KROS) 株価情報

KEROS THERAPEUTICS INC

Keros Therapeutics

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Keros Therapeutics Inc

KROSAKI HARIMA CORP by KROSAKI HARIMA CORP.

Registration Link for Presentation to take place Thursday, May 22, 2025 at 10:00 AM ET
Marlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL&#xAE; gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Mr. Bitterman will also host one-on-one meetings with investors at the conference, taking place on May 21-22, 2025.
Phio's presentation will begin at 10 AM ET on May 22, 2025 and can be accessed live here: &nbsp;&nbsp; WEBCAST LINK FOR PHIO'S PRESENTATION: <a href="https://api.newsfilecorp.com/redirect/7W7Z2tk0e3">Webinar Registration - Zoom</a>

News

PHIO

Phio Pharma To Present Update On Proprietary INTASYL Sirna Technology And Progress On On-Going Clinical Trial With Lead Compound PH-762 For Treatment Of Skin Cancers

TopBuild Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>), a leading installer and specialty distributor of insulation and building material products to the construction industry in the United States and Canada, today announced the extension and upsizing of its existing senior secured credit facilities. The new $2.25 billion facilities include a $1.0 billion term loan, a $1.0 billion revolving credit facility and a $250.0 million delayed draw term loan, each maturing in May 2030.

TopBuild Secures $2.25 Billion Credit Deal to Fuel Growth Through 2030

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4429760-1&amp;h=351561060&amp;u=http%3A%2F%2Fwww.jacobs.com%2F&amp;a=Jacobs">Jacobs</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) to advance data centers via NVIDIA's Omniverse Blueprint for AI <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4429760-1&amp;h=1064221003&amp;u=https%3A%2F%2Fblogs.nvidia.com%2Fblog%2Fomniverse-blueprint-ai-factories-expands&amp;a=NVIDIA+">NVIDIA </a><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4429760-1&amp;h=2737473039&amp;u=https%3A%2F%2Fblogs.nvidia.com%2Fblog%2Fomniverse-blueprint-ai-factories-expands&amp;a=Omniverse+Blueprint+for+AI+factory+digital+twins">Omniverse Blueprint for AI factory digital twins</a> – a blueprint to improve the design, simulation, deployment and operations of AI factories.
Jacobs will test and enhance the end-to-end blueprint workflow, enabling accurate simulations of facility equipment efficiency, throughput and resiliency. Created to unify the design and simulation of billions of components to build digital twins of AI Factories, the blueprint will introduce new integrations across the AI Factory's power, cooling and network ecosystems. Through this collaboration, engineering teams can design, simulate and optimize factories within physically accurate virtual environments, enabling early issue detection and the creation of smarter, more reliable facilities.

NVDA

Jacobs Joins Nvidia to Build Smarter AI Data Centers With Omniverse Digital Twin Blueprint

IES Holdings, Inc. (or "IES" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NASDAQ">IESC</a>) announced today that Matthew Simmes, President and Chief Operating Officer, will succeed Jeffrey Gendell as Chief Executive Officer effective July 1, 2025, in accordance with the Company's executive succession plan. In addition, Mr. Simmes will continue in his role as President of the Company and will join the Board of Directors. Mr. Gendell, who was appointed Chairman of the Board in 2016 and Chief Executive Officer in 2020, will become Executive Chairman and will continue to lead the Board of Directors while working closely with Mr. Simmes and the rest of IES's senior leadership team.

Management

IESC

IES Holdings Says Matthew Simmes, President and COO, To Succeed Jeffrey Gendell As CEO, Effective July 1, 2025

UBS analyst Thomas Wadewitz upgrades United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) from Neutral to Buy and raises the price target from $67 to $105.

Upgrades

Price Target

Analyst Ratings

UBS Upgrades United Airlines Holdings to Buy, Raises Price Target to $105

WIIM

PTIX

Protagenic Therapeutics shares are trading higher after the company entered a business combination with Phytanix

DOCS reverses steep decline after TradePulse Alert
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/16201031/Screenshot-2025-05-16-at-4.10.03%E2%80%AFPM-1024x1019.png" alt="" class="wp-image-13042" /></figure>
Doximity Inc. (DOCS) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:10 AM on May 15th, a significant trading signal occurred for Doximity Inc., (DOCS) as it demonstrated a Power Inflow at a price of $49.24. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Doximity's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Doximity's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for DOCS, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025">https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025</a>, which are responsible for parts of the data within this article.
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close UPDATE:
The price at the time of the Power Inflow was $49.24. The returns on the High price ($53.08) and Close price ($52.56) after the Power Inflow are respectively 7.8% and 6.7%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your appetite for risk.

Equities

Technicals

Opinion

Signals

Trading Ideas

DOCS

Doximity Stock 7.8% Higher After Key Trading Signal

Structure of Combination
Under the terms of the Exchange Agreement, the Company, in exchange for all of the outstanding shares of Phytanix Bio, issued on a pro rata basis to each of the common stockholders of Phytanix Bio, an aggregate of (A) 117,690 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), which shares represent a number equal to no more than 19.99% of the outstanding shares of Common Stock as of immediately before the closing on May 16, 2025, (B) 5,705 shares of the Company's Series C Convertible Preferred Stock, par value $0.000001 per share (the "Series C"), and (C) 950,000 shares of the Company's Series C-1 Convertible Preferred Stock, par value $0.000001 per share (the "Series C-1"). In addition, in exchange for all of the outstanding preferred stock of Phytanix Bio, the Company issued on a pro rata basis to each of PHX's preferred stockholders an aggregate of (i) 20,000 shares of Series D Preferred Stock, par value $0.000001 per share of the Company (the "Series D" together with the Series C and Series C-1, the "Preferred Stock"), and (ii) common stock purchase warrants to purchase up to 715,493 shares of common stock (the "Warrants"). The issuance of the shares of Common Stock, the Preferred Stock, and the Warrants occurred on May 16, 2025. Each share of Preferred Stock is convertible into one of common stock, subject to certain conditions described in the Exchange Agreement.
As calculated on a fully diluted basis, post-Combination pre-financing ownership will be approximately 35% for the pre-Combination stockholders of the Company and approximately 65% for Phytanix Bio stockholders.
The issuance of shares of common stock upon conversion of the Preferred Stock and exercise of the Warrants issued in the Combination shall be subject to stockholder approval in compliance with the rules of the Nasdaq Stock Market.

As Calculated On A Fully Diluted Basis, Post-Combination Pre-Financing Ownership Will Be Approximately 35% For The Pre-Combination Stockholders Of The Company And Approximately 65% For Phytanix Bio Stockholders.

Protagenic Therapeutics And Phytanix Enter Business Combination In All-Stock Transaction

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.juniper.net%2F&amp;esheet=54256691&amp;newsitemid=20250519198117&amp;lan=en-US&amp;anchor=Juniper+Networks&amp;index=1&amp;md5=dd335110fb5c08ac0506864b07063ea5">Juniper Networks</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>), a leader in secure, AI-native networks, extends its partnership with ServiceNow to integrate Juniper's <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.juniper.net%2Fus%2Fen%2Fmist-ai-native-networking-platform.html&amp;esheet=54256691&amp;newsitemid=20250519198117&amp;lan=en-US&amp;anchor=AI-native+networking+platform&amp;index=2&amp;md5=fef3486e3bef0d28c8dc5874b0009414">AI-native networking platform</a>, Mist&#x2122;, with ServiceNow <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.servicenow.com%2Fproducts%2Ftelecommunications-service-management.html&amp;esheet=54256691&amp;newsitemid=20250519198117&amp;lan=en-US&amp;anchor=Telecom+Service+Management&amp;index=3&amp;md5=7a6efed7fe8295ff7f4d4ad0cbbe77d7">Telecom Service Management</a>, Inventory and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.servicenow.com%2Fproducts%2Ftelecom-order-management.html&amp;esheet=54256691&amp;newsitemid=20250519198117&amp;lan=en-US&amp;anchor=Sales+%26amp%3B+Order+Management&amp;index=4&amp;md5=f7639557085b7baf2e5ec49ef0014a87">Sales &amp; Order Management</a> for Telecom. The combined solution brings end-to-end network and service automation together with AI-native, cloud-native and 100 percent API-driven wired, wireless and SD-WAN solutions to drive business transformation and deliver unparalleled efficiencies and cost savings to enterprises and MSPs. This integration is the first of its kind for the solution.
 &nbsp;

JNPR

Juniper Networks Extends Partnership With Servicenow To Integrate Juniper's AI-Native Networking Platform, Mist, With Servicenow Telecom Service Management, Inventory And Sales & Order Management For Telecom

UBS analyst Thomas Wadewitz upgrades Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) from Neutral to Buy and raises the price target from $46 to $66.

UBS Upgrades Delta Air Lines to Buy, Raises Price Target to $66

UBS analyst Manav Gupta upgrades Archer-Daniels-Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) from Neutral to Buy and raises the price target from $55 to $60.

UBS Upgrades Archer-Daniels-Midland to Buy, Raises Price Target to $60

Wolfe Research analyst Andy Chen upgrades MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) from Peer Perform to Outperform and announces $61 price target.

MLTX

Wolfe Research Upgrades MoonLake to Outperform, Announces $61 Price Target

Citigroup analyst Andres Cardona upgrades YPF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YPF#NYSE">YPF</a>) from Neutral to Buy and raises the price target from $44 to $48.

Citigroup Upgrades YPF to Buy, Raises Price Target to $48

Guidance

NVAX

Novavax Reiterates Expectation To Achieve R&D Plus SG&A Expenses For FY25 Of Between $475M-$525M. For 2026 And 2027, Expects To Reduce R&D Plus SG&A Expenses To Approximately $350M And $250M, Respectively

Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#CSE">QNTM</a>) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased an additional USD $1,000,000 worth of Bitcoin (BTC) and other cryptocurrencies as part of its strategic efforts. This brings the total amount of BTC and other cryptocurrencies purchased to USD $4,500,000. As previously announced the company will continue to allow for future financing and other transactions to be carried out in cryptocurrency.

CSE:QNTM

QNTM

Quantum Biopharma Purchases Additional $1M Worth Of Bitcoin And Other Cryptocurrencies As Part Of Strategic Efforts, Bringing Total Investment In Digital Assets To $4.5M

Citigroup analyst Scott Gruber downgrades Helmerich &amp; Payne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) from Buy to Neutral and lowers the price target from $25 to $19.

Downgrades

Citigroup Downgrades Helmerich & Payne to Neutral, Lowers Price Target to $19

HC Wainwright &amp; Co. analyst Robert Burns maintains Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) with a Buy and lowers the price target from $12 to $11.

YMAB

HC Wainwright & Co. Maintains Buy on Y-mAbs Therapeutics, Lowers Price Target to $11

U.S. President Donald Trump has demanded a comprehensive investigation into the celebrity endorsements received by Kamala Harris during the 2024 election. He alleges that these endorsements involved illegal compensation.
What Happened:&nbsp;Trump took to his Truth Social early Monday and singled out celebrities like Bruce Springsteen, Beyoncé, Oprah Winfrey and Bono, who publicly backed Harris.&nbsp;He made claims that these endorsements were bought, which he believes is against the law.
Trump accused Harris of disguising payments for entertainment as compensation for these celebrity endorsements. He went on to label the artists who supported Harris as &#8220;unpatriotic.&#8221;
Harris&#8217; Office did not immediately respond to Benzinga&#8217;s request for comment. 
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="610" height="473" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19063509/image-225.png" alt="" class="wp-image-919578" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19063509/image-225.png 610w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19063509/image-225-300x233.png 300w" sizes="(max-width: 610px) 100vw, 610px" /></figure>
However, Politico reported that these allegations have been refuted by Beyoncé&#8217;s mother and Winfrey, who insisted that the artists did not receive any personal fees for their endorsements. Campaign finance records indicate that Harris&#8217; campaign paid $165,000 to Beyoncé&#8217;s production company and&nbsp;$1 million was paid to Winfrey&#8217;s company, Harpo Productions.
Despite raising over&nbsp;$1 billion in just a&nbsp;few months, the Harris campaign has been subject to rumors of paying millions to celebrities for their support. These rumors have been categorically denied by the celebrities&#8217; teams.
SEE ALSO: <a href="https://benzinga.com/news/global/25/05/45487501/trump-pushes-for-russia-ukraine-ceasefire-to-end-bloodbath-in-high-stakes-calls-with-russian-president-and-zelenskyy-amid-drone-attacks" target="_blank" rel="noreferrer noopener">Trump Pushes For Russia-Ukraine Ceasefire To End &#8216;Bloodbath&#8217; In High-Stakes Calls With Russian President And Zelenskyy Amid Drone Attacks</a>
Why It Matters: Trump lashed out at Bruce Springsteen last week, calling him "not a talented guy" and criticizing his appearance, after the musician labeled the Trump administration "corrupt, incompetent and treasonous" during a concert in England.
Notably, the 2024 election saw a significant increase in celebrity involvement in politics. Following Trump&#8217;s second victory, several high-profile celebrity Americans announced plans to <a href="https://www.benzinga.com/real-estate/24/11/41982378/trumps-win-has-celebrities-saying-goodbye-america-see-where-theyre-going">relocate </a>abroad in November 2024.
Moreover, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk actively <a href="https://www.benzinga.com/news/24/10/41561298/elon-musk-pumps-more-than-130m-into-trump-and-gop-campaigns">campaigned </a>for Trump, investing over $130 million in Trump and GOP campaigns. Meanwhile, Politico reported that Trump has actively sought celebrity endorsements in all three of his presidential campaigns, including from figures like Kanye West and Kid Rock, who even appeared at key events like the Republican National Convention and his inauguration-eve rally.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/05/45486040/chuck-schumer-raises-concerns-over-trump-and-doge-impact-on-us-coast-guard-after-mexican-ship-collides-with-brook" target="_blank" rel="noreferrer noopener">Chuck Schumer Raises Concerns Over Trump And DOGE Impact On US Coast Guard After Mexican Ship Collides With Brooklyn Bridge: &#8216;We Know They&#8217;ve Been Meddling&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

TSLA

Did Kamala Harris Pay For Endorsements From Beyoncé, Springsteen, Oprah Winfrey? Trump Demands 'Major Investigation'

Transformational Acquisition Increases Sanmina's Scale and End-Market Exposure to Cloud and AI Infrastructure
Planned Divestiture by AMD Creates Preferred NPI Manufacturing Partnership with Sanmina, a Leading IMS Company
Purchase Price of $2.55 Billion Cash and Equity, Plus $450 Million in Contingent Consideration, Totaling Up to $3 Billion
Transaction Expected to be Accretive to Non-GAAP EPS in First Year Post-Close
Sanmina to Host Conference Call Today at 8:30 a.m. ET (5:30 a.m. PT)
SAN JOSE, Calif., May 19, 2025 /PRNewswire/ -- Sanmina Corporation ("Sanmina") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>), a leading integrated manufacturing solutions company, today announced that it has entered into a definitive agreement to acquire the data center infrastructure manufacturing business of ZT Systems, a leading provider of Cloud and AI infrastructure to the world's largest hyperscalers, from AMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>). The strategic acquisition further establishes Sanmina's position as an industry-leading, vertically integrated global manufacturing solutions provider that can now also accelerate its customers' at scale deployments of cutting-edge AI systems for the data center.
As a combined company, Sanmina expects to strengthen its leading end-to-end component technology, systems integration and supply chain solutions to deliver even greater value for its customers. ZT Systems' current annual net revenue run-rate is approximately $5 - $6 billion and the outlook ahead is promising as new accelerated compute platforms are launched. In addition, ZT Systems' manufacturing team brings over 30 years of systems integration experience and has evolved into a leading provider of high-performance Cloud and AI infrastructure for hyperscalers. The company's advanced liquid cooling capabilities and manufacturing facilities in New Jersey, Texas and the Netherlands, together with its global supply chain, position it to offer end-to-end systems integration, from components to complete racks, for the Cloud and AI infrastructure ecosystem.

SANM

Sanmina To Acquire Data Center Infrastructure Manufacturing Business Of ZT Systems From AMD In $3B Deal; Transaction Expected To Be Accretive To Non-GAAP EPS In First Year Post-Close

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS

Earnings

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Health Care

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Keros Therapeutics Announces Review of Strategic Alternatives

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

Keros Reinforces Commitment to Maximizing Stockholder Value

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

Comments

Keros Therapeutics

ニュース

パートナーシップ

ベンジンガ・グローバル